Elevating Precision in Kidney Injury Management: Unraveling the Impact of Serum Cystatin C Levels – A Cohort Study in Lahore Hospitals

Main Article Content

Muhammad Faisal Rafiq
Zarrien Fatima
Hafiz Muhammad Haseeb Khaliq
Ashbail Nasir
Muhammad Noman Tahir
Aqsa Yasin
Iqra Sarwar


Background: Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) pose significant challenges in clinical diagnostics due to late presentation and the influence of non-renal factors on traditional biomarkers. Serum creatinine, while commonly used, lacks sensitivity in early-stage kidney dysfunction due to its delayed elevation post-reduction in glomerular filtration rate (GFR). Serum cystatin C, on the other hand, is not influenced by muscle mass, age, gender, or ethnicity, and thus presents as a potential early biomarker for kidney injury.

Objective: The objective of this study was to evaluate the efficacy of serum cystatin C compared to serum creatinine in early detection of renal dysfunction in AKI patients, assessing its correlation with renal decline and potential as a predictor for patient outcomes.

Methods: In a cohort study over two years at a tertiary care hospital, 200 healthy individuals and 130 AKI patients were assessed. Serum cystatin C and creatinine levels were measured using ELISA and chemiluminescent immunoassay (CLIA) respectively. Demographics, clinical statistics, and Pearson correlation coefficients were calculated, followed by multiple logistic regression analyses for GFR. Statistical significance was established at P<0.001.

Results: Results indicated that in the early phase of AKI, 56.2% of patients had normal serum creatinine levels, whereas serum cystatin C levels were elevated in all patients. The Pearson Correlation Coefficient between serum creatinine and cystatin C was significant (<0.01). Multiple logistic regression revealed cystatin C-based GFR was a more reflective indicator of declining GFR than creatinine-based GFR (P<0.001).

Conclusion: Serum cystatin C is a superior biomarker to serum creatinine for early detection of kidney dysfunction in AKI patients, facilitating earlier and potentially more effective therapeutic interventions. This finding could lead to significant improvements in patient prognosis and the management of kidney disease.

Article Details

How to Cite
Rafiq, M. F., Fatima, Z., Khaliq, H. M. H., Nasir, A., Tahir, M. N., Yasin , A., & Sarwar, I. (2024). Elevating Precision in Kidney Injury Management: Unraveling the Impact of Serum Cystatin C Levels – A Cohort Study in Lahore Hospitals. Journal of Health and Rehabilitation Research, 4(1), 1186–1191. https://doi.org/10.61919/jhrr.v4i1.597
Author Biographies

Muhammad Faisal Rafiq, University of Health Sciences Lahore Pakistan.

Department of Allied Health Sciences University of Health Sciences, Lahore, Pakistan.

Zarrien Fatima, Kinnaird College For Women University Lahore Pakistan.

Department of Zoology Kinnaird College for Women University, Lahore, Pakistan.

Hafiz Muhammad Haseeb Khaliq, University of Health Sciences Lahore Pakistan.

Department of Allied Health Sciences University of Health Sciences, Lahore, Pakistan.

Ashbail Nasir, Riphah International University Faisalabad Pakistan.

Riphah College of Allied Health Sciences, Riphah International University, Faisalabad, Pakistan.

Muhammad Noman Tahir, Government College University Faisalabad Pakistan.

Department of Allied Health Professionals, Government College University, Faisalabad, Pakistan.

Aqsa Yasin , University of South Asia Lahore Pakistan.

Lecturer, Department of Allied Health Sciences University of South Asia, Lahore, Pakistan.

Iqra Sarwar, University of Health Sciences Lahore Pakistan.

Department of Allied Health Sciences University of Health Sciences, Lahore, Pakistan.


Mullins LJ, Conway BR, Menzies RI, Denby L, Mullins JJ. Renal disease pathophysiology and treatment: contributions from the rat. Dis Model Mech. 2016;9(12):1419-33.

Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294-304.

Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. Am J Med. 2016;129(2):153-162.e7.

Akbari A, Clase CM, Acott P, Battistella M, Bello A, Feltmate P, et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis. 2015;65(2):177-205.

Koye DN, Magliano DJ, Reid CM, Jepson C, Feldman HI, Herman WH, et al. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2018;72(5):653-61.

Fernando S, Polkinghorne KR. Cystatin C: not just a marker of kidney function. J Bras Nefrol. 2020;42(1):6-7.

Ayub S, Zafar MN, Aziz T, Iqbal T, Khan S, Rizvi SA. Evaluation of renal function by cystatin C in renal transplant recipients. Exp Clin Transplant. 2014;12(1):37-40.

Garg P, Hidalgo G. Glomerular Filtration Rate Estimation by Serum Creatinine or Serum Cystatin C in Preterm (<31 Weeks) Neonates. Indian Pediatr. 2017;54(6):508-9.

Rebholz CM, Grams ME, Matsushita K, Inker LA, Foster MC, Levey AS, et al. Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality. Clin J Am Soc Nephrol. 2015;10(6):941-8.

Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295-300.

Ghys L, Paepe D, Smets P, Lefebvre H, Delanghe J, Daminet S. Cystatin C: a new renal marker and its potential use in small animal medicine. J Vet Intern Med. 2014;28(4):1152-64.

Dandana A, Gammoudi I, Chalghoum A, Chahed H, Addad F, Ferchichi S, et al. Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease. J Clin Lab Anal. 2014;28(3):191-7.

Sai E, Shimada K, Miyauchi K, Masaki Y, Kojima T, Miyazaki T, et al. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Heart Vessels. 2016;31(5):694-701.

Wang J, Sim AS, Wang XL, Salonikas C, Moriatis M, Naidoo D, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008;197(2):853-9.

Chen Z, Zhang J, Feng J, Zhou G, Jin X, Pan J. Higher serum level of Cystatin C: An additional risk factor of CAD. Medicine (Baltimore). 2021;100(2):e24269.

Qiu X, Liu C, Ye Y, Li H, Chen Y, Fu Y, et al. The diagnostic value of serum creatinine and cystatin C in evaluating glomerular filtration rate in patients with chronic kidney disease: a systematic literature review and meta-analysis. Oncotarget. 2017;8(42):72985-99.

Pandey VK, Mazumdar PM, Vidyapati, Prasad ML. Study of Serum Cystatin C and Serum Creatinine in Different Stages of Chronic Kidney Disease Patients. J Assoc Physicians India. 2022;70(4):11-2.

Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006;69(2):399-405.

Ciin MN, Proungvitaya T, Limpaiboon T, Roytrakul S, Cha'on U, Tummanatsakun D, et al. Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma. Int J Hematol Oncol Stem Cell Res. 2020;14(3):157-66.

Meeusen JW, Rule AD, Voskoboev N, Baumann NA, Lieske JC. Performance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics. Clin Chem. 2015;61(10):1265-72.

Most read articles by the same author(s)